CTLA4 and myocarditis: Subsequently, Wei et al. identify a preclinical mouse model of ICI-related myocarditis (Ctla4+/−Pdcd1−/−mice) induced by this combination therapy, and prove that intervention treatment with Abatacept (a recombinant soluble fusion protein of CTLA-4) inhibits T cell co-stimulation and improves disease progression [457].